Osimertinib Monotherapy or Combination With Chemotherapy for Advanced NSCLC Concurrent EGFR and TP53 Mutations

NCT04695925 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

294

Enrollment

OTHER

Sponsor class

Conditions

Non-small Cell Carcinoma
EGFR Gene Mutation

Interventions

DRUG: Osimertinib
DRUG: Pemetrexed
DRUG: Carboplatin

Sponsor

Li Zhang, MD

Collaborators

[object Object]
[object Object]
[object Object]